BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 1818301)

  • 1. p53 gene alterations in human hematological malignancies: a review.
    Soussi T; Jonveaux P
    Nouv Rev Fr Hematol (1978); 1991; 33(6):477-80. PubMed ID: 1818301
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Mutations of the p53 gene in hematologic neoplasms].
    Mori N; Mizoguchi H
    Nihon Rinsho; 1992 Jun; 50(6):1353-7. PubMed ID: 1518157
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression patterns of costimulatory molecules on cells derived from human hematological malignancies.
    Zheng Z; Takahashi M; Aoki S; Toba K; Liu A; Osman Y; Takahashi H; Tsukada N; Suzuki N; Nikkuni K; Furukawa T; Koike T; Aizawa Y
    J Exp Clin Cancer Res; 1998 Sep; 17(3):251-8. PubMed ID: 9894758
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [P53 genes and malignant hematologic diseases].
    Jonveaux P
    Bull Cancer; 1993 Aug; 80(8):697-703. PubMed ID: 8204951
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Rearrangement and expression of bcr-abl genes in CML and ALL].
    Kunieda Y; Okabe M
    Rinsho Ketsueki; 1991 Jun; 32(6):623-8. PubMed ID: 1890738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Molecular analysis of transformation into blast crisis in chronic myelogenous leukemia].
    Okabe M
    Hokkaido Igaku Zasshi; 1993 Mar; 68(2):237-50. PubMed ID: 8509066
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [p53 and hematologic malignancies].
    Preudhomme C; Fenaux P
    Pathol Biol (Paris); 1997 Dec; 45(10):898-908. PubMed ID: 9769955
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic alterations in the p53 gene in the blast crisis of chronic myelogenous leukemia: analysis by polymerase chain reaction based techniques.
    Neubauer A; He M; Schmidt CA; Huhn D; Liu ET
    Leukemia; 1993 Apr; 7(4):593-600. PubMed ID: 8464238
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Molecular study on minute alterations of the p53 and the N-ras genes in hematologic malignancies].
    Kurosawa M
    Hokkaido Igaku Zasshi; 1994 May; 69(3):543-54. PubMed ID: 7927179
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of cell cycle regulatory genes in chronic myelogenous leukemia.
    Iolascon A; Della Ragione F; Giordani L; Serra A; Saglio G; Faienza MF
    Haematologica; 1998 Sep; 83(9):771-7. PubMed ID: 9825572
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retroviral transduction of Philadelphia-positive chronic myeloid leukemia cells with a human mutant p53 cDNA and its effect on in vitro proliferation.
    Bi S; Barton CM; Lemoine NR; Cross NC; Goldman JM
    Exp Hematol; 1994 Jan; 22(1):95-9. PubMed ID: 8282066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of p53 in leukemogenesis of chronic myeloid leukemia.
    Lanza F; Bi S
    Stem Cells; 1995 Jul; 13(4):445-52. PubMed ID: 7549904
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decreases in Ikaros activity correlate with blast crisis in patients with chronic myelogenous leukemia.
    Nakayama H; Ishimaru F; Avitahl N; Sezaki N; Fujii N; Nakase K; Ninomiya Y; Harashima A; Minowada J; Tsuchiyama J; Imajoh K; Tsubota T; Fukuda S; Sezaki T; Kojima K; Hara M; Takimoto H; Yorimitsu S; Takahashi I; Miyata A; Taniguchi S; Tokunaga Y; Gondo H; Niho Y; Harada M
    Cancer Res; 1999 Aug; 59(16):3931-4. PubMed ID: 10463586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutations of the WT1 gene in childhood nonlymphoid hematological malignancies.
    Miyagawa K; Hayashi Y; Fukuda T; Mitani K; Hirai H; Kamiya K
    Genes Chromosomes Cancer; 1999 Jun; 25(2):176-83. PubMed ID: 10338002
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The effect of the tumor suppressor p53 and its mutant forms on the differentiation and viability of K562 leukemic cells].
    Kremenetskaia OS; Logacheva NP; Baryshnikov AIu; Chumakov PM; Kopnin BP
    Tsitologiia; 1996; 38(12):1280-93. PubMed ID: 9163103
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rearrangement and expression of the p53 gene in myelodysplastic syndrome and acute myeloid leukemia.
    Fenaux P; Collyn d'Hooghe M; Jonveaux P; Lai JL; Bauters F; Loucheux MH; Kerckaert JP
    Nouv Rev Fr Hematol (1978); 1990; 32(5):341-4. PubMed ID: 2099408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The usefulness of the bcr/abl rearrangement in the diagnosis and evolution of chronic myeloid leukemia].
    González FA; Villegas A; Ferro MT; San Román C; Sáez I; López M; del Potro E; Alvarez A; Martínez R; Díaz Madiavilla J
    Med Clin (Barc); 1993 Oct; 101(14):521-4. PubMed ID: 8231395
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Model mice for BCR/ABL-positive leukemias.
    Honda H; Hirai H
    Blood Cells Mol Dis; 2001; 27(1):265-78. PubMed ID: 11358387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. P53, p15INK4B, p16INK4A and p57KIP2 mutations during the progression of chronic myeloid leukemia.
    Güran S; Bahçe M; Beyan C; Korkmaz K; Yalçin A
    Haematologia (Budap); 1998; 29(3):181-93. PubMed ID: 10069444
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Breakpoint cluster region, immunoglobulin, and T-cell receptor gene rearrangement analysis in juvenile chronic myelogenous leukemia.
    Farhi DC; Luckey CN; Siddiqui AM
    Mod Pathol; 1995 May; 8(4):389-93. PubMed ID: 7567936
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.